These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18838209)

  • 1. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Tombal B
    Eur Urol; 2009 Feb; 55(2):321. PubMed ID: 18838209
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Sciarra A
    Eur Urol; 2009 Feb; 55(2):320-1. PubMed ID: 18838210
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Abraham Morgentaler, Abdulmaged M. Traish. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-21.
    Friedman AE
    Eur Urol; 2009 Jul; 56(1):e4; author reply e5. PubMed ID: 19349108
    [No Abstract]   [Full Text] [Related]  

  • 4. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Morgentaler A; Traish AM
    Eur Urol; 2009 Feb; 55(2):310-20. PubMed ID: 18838208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noble PRST-1 Ca prostate adenocarcinoma study on noble rats: preliminary study on new androgen sensitive tumor.
    Wientjes G; Smith J; Miller R; Badalament RA; Drago JR
    In Vivo; 1989; 3(5):335-7. PubMed ID: 2519875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
    Morgentaler A
    J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts in studying the control of normal and cancer growth of the prostate.
    Coffey DS; Pienta KJ
    Prog Clin Biol Res; 1987; 239():1-73. PubMed ID: 3309951
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
    van der Poel HG
    Eur Urol; 2009 Jul; 56(1):103-4. PubMed ID: 19282103
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of testosterone in the pathogenesis of prostate cancer.
    Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Nihei N; Naya Y; Ichikawa T
    Int J Urol; 2008 Jun; 15(6):472-80. PubMed ID: 18430151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach.
    Gardiner RA; Sweeney C; Tilley WD
    Eur Urol; 2009 Aug; 56(2):245-6. PubMed ID: 19409691
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolism of adrenal androgen and its impacts on prostate cancer after castration.
    Hu MQ; Na YQ
    Chin Med J (Engl); 2008 Feb; 121(4):369-74. PubMed ID: 18304472
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate cancer, gonadal hormones, and my brain.
    Wassersug RJ
    J Sex Marital Ther; 2014; 40(5):355-7. PubMed ID: 24846435
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment.
    Agarwal PK
    J Urol; 2011 Apr; 185(4):1261. PubMed ID: 21334657
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment.
    Miner MM
    J Urol; 2011 Apr; 185(4):1261. PubMed ID: 21334686
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
    Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
    Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone Therapy and Prostate Cancer.
    Davidson E; Morgentaler A
    Urol Clin North Am; 2016 May; 43(2):209-16. PubMed ID: 27132578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Androgen deficiency in males and its correction in respect to pathogenesis of prostatic cancer].
    Mazo EB; Grigor'ev ME; Konorev VA; Ermisheva OM
    Urologiia; 2008; (3):57-8, 60-2. PubMed ID: 18669351
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: Hedgehog signalling in androgen independent prostate cancer.
    Chen M; Buttyan R
    Eur Urol; 2008 Dec; 54(6):1341-3. PubMed ID: 18262714
    [No Abstract]   [Full Text] [Related]  

  • 20. Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology.
    Hafez B; Hafez ES
    Arch Androl; 2004; 50(2):45-68. PubMed ID: 14761837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.